Guttate psoriasis induced by infliximab in a child with Crohn's disease.

and the mechanism of Crohn’s disease. More and more evidence has suggested that gut bacteria play a critical role in the development of inflammatory bowel disease, and Crohn’s disease seems to develop in the intestine largely as a result of aberrant interaction of gut bacteria and their components with the host. If this is true, we would have to answer how Crohn’s disease with the same nature occurred in the mouth and esophagus, where the amount of bacteria is very limited. Lesions of the intestine can usually be found at the same time or eventually show up in patients with “Crohn’s disease of the esophagus or the mouth.” It seems that lesions of the esophagus and mouth are more likely to be manifestations of intestinal Crohn’s disease rather to have originated locally. If this is the case, the lesions of the esophagus and mouth should probably be called oral or esophageal manifestations (or complications) of Crohn’s disease rather Crohn’s disease of the esophagus or the mouth, just like the uveitis in Crohn’s patients would be better called a manifestation of Crohn’s disease in the eye rather Crohn’s disease of the eye. Saying that Crohn’s disease can occur anywhere in the digestive tract seems to be a convenient but potentially misleading statement.

[1]  M. Scheinberg,et al.  The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. , 2008, Seminars in arthritis and rheumatism.

[2]  R. Caprilli,et al.  Another paradox in Crohn's disease: new onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist. , 2007, Inflammatory bowel diseases.

[3]  A. Griffiths,et al.  Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. , 2007, Gastroenterology.

[4]  E. Dauden,et al.  Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers , 2007, Clinical and experimental dermatology.

[5]  C. Roux,et al.  New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect? , 2007, The Journal of rheumatology.

[6]  C. Kittas,et al.  Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. , 2005, Arthritis and rheumatism.

[7]  R. Baldassano,et al.  Extraintestinal manifestations of inflammatory bowel disease. , 2005, Minerva gastroenterologica e dietologica.

[8]  E. Fonseca,et al.  Psoriasiform Eruption Induced by Infliximab , 2004, The Annals of pharmacotherapy.

[9]  A. Gottlieb,et al.  Connections between psoriasis and Crohn's disease. , 2003, Journal of the American Academy of Dermatology.

[10]  W. Sandborn,et al.  Crohn’s Disease of the Esophagus: Clinical Features and Outcomes , 2001, Inflammatory bowel diseases.

[11]  A. Dupuy,et al.  Oral Crohn disease: clinical characteristics and long-term follow-up of 9 cases. , 1999, Archives of dermatology.

[12]  H. Chon,et al.  Crohn's disease of the esophagus. , 1975, The American journal of roentgenology, radium therapy, and nuclear medicine.

[13]  I. Todd,et al.  Crohn's Disease of the Mouth , 1969, Proceedings of the Royal Society of Medicine.